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INTRODUCTION  
The term NAFLD was coined by Ludwig et al in 1980, it is a 
spectrum of liver diseases with histologic features of  alcohol – induced 
liver disease that occurs in individuals who do not consume significant 
quantities of alcohol. 
 
The spectrum includes  
1) Fatty liver (hepatic steatosis)  
2) NASH – Non alcoholic steatohepatitis  
3) Cirrhosis  
Clinically NAFLD is a diagnosis of exclusion of other causes of 
liver disease . It is characterized  histologically by excessive accumulation 
of   hepatic fat in the absence of alcohol consumption .  NAFLD is a major 
cause of liver related to morbidity and mortality.  A complete diagnosis of 
fatty liver disease ideally should define the histology, including the stage 
and grade of  the disease as well as its etiology.  It is commonly associated 
with metabolic syndrome. 80% patient with metabolic syndrome have 
NAFLD .The risk factors  for  non alcoholic steatohepatits are obesity , 
type 2 diabetes mellitus , drugs, female gender, hypertriglyceridemia, 
hypercholesterolemia. Most patients with fatty liver have insulin 
resistance. 
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Since the prevalence of fatty liver is increasingly seen in East Asian 
and India than in western countries this study includes the calculated data 
for  finding the at risk group in our population.  
 
EPIDEMOLOGY  
 
The prevalence of NAFLD varies from 10 – 24 % in general 
population.  Fatty liver has been documented in 10 – 15 % of normal 
population and 70 -80% of obese population. NAFLD in the general 
population ranges from 9.3 to 29% in Asia 1 
 
The prevalence of NAFLD varies due to difficulty in diagnosis. 
Population based studies have revealed that NAFLD is more common in 
men than in women . Recent studies have shown that NAFLD has a more 
even distribution between men and women.9most cases occurs in 4th and 
6th decade . In a population-based study in the United States, Browning et 
al found that individuals with magnetic resonance spectroscopy defined-
NAFLD were slightly older (46 versus 45 years old, p = 0.003) than those 
with normal2 Of particular concern is that NAFLD is increasing in the 
pediatric population with a prevalence of 3 % in normal children and 20 -
50 % in obese children 3 Familial clustering occurs in NAFLD. The causes 
of such familial clustering include both genetic and environmental factors. 
A clear-cut pattern of inheritance of risk for NAFLD was not identified 4 
Several instances of fatty liver also have been described in patients with 
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rare familial disorders (e.g., hypobetalipoproteinemia) diabetes and 
hemolytic anemia due to a deficiency of red cell Mg2_–adenosine 
triphosphatase. In such cases, despite the presence of an underlying 
familial disorder, no systematic studies of the prevalence of fatty liver or 
steatohepatitis in the affected families have been reported. 
 
Hispanics, East Asians and Indians are more predisposed ethnic 
groups compared to Caucasian and afro Americans.  In one study , the 
estimated prevalence ranges from 3% to 24%.5 NAFLD is extremely 
common among patients undergoing bariatric surgery, ranging from 84% 
to 96%. In these patients, 25% to 55% have NASH, 34% to 47% have 
fibrosis, and 2% to 12% have bridging fibrosis or cirrhosis. 
 
The Dallas Heart Study of more than 2200 adults documented 
hepatic triglycerides content by proton magnetic resonance spectroscopy 
and found fatty liver in 31% of participants , the highest prevalence (45%) 
among Hispanics.2 
 
Population  based  estimates of NAFLD have been reported for other 
countries  as well , these studies have documented NAFLD  in 10% to 24% 
of the population with 76% among obese non – drinkers The prevalence of 
NAFLD  is 50% in people with diabetes , 74% in obese and nearly 100% 
in morbidly obese individuals 6 NAFLD is a independent risk factor for 
cardiovascular mortality. More recently, several biopsy studies among both 
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living and cadaveric liver donors have been published. The prevalence of 
NAFLD among living liver donors ranges from 17.9% in Japan 7,8 
 
PATHOGENESIS   
 
Hepatic steatosis is caused by imbalance between the deliver or 
synthesis of fat in the liver .It is complex , potentially involving multiple 
tissues including the liver , adipose tissue muscle and other peripheral 
tissues.in the presence of excess calories,the rates of lipolysis and 
lipogenesis  are affected , leading to release of free fatty acids into 
circulation this influences the accumulation of lipids in liver and peripheral 
tissues.and cytokines are released and impair insulin signaling and reduce 
insulin mediated glucose uptake. All these are accompanied by impaired 
apolipoprotein B 100 and formation of very low density lipoprotein.All 
these factors trigger lipid accumulation and oxidation in the liver , 
oxidative stress, the release of inflammatory cytokines, and hepatic stellate 
cell activation. 
 
NASH develops as a consequence of two hit process  First hit is 
accumulation of  free fatty acids and triglycerides within liver . Second hit 
is fatty accumulation leading to chronic oxidative stress 
 
Mechanism of first hit steatosis – insulin sensitivity of adipocytes 
depends on profile of adipokines – TNF alpha , leptin, adipokinin,sex 
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hormones,fatty acids , resistin and cortisol. A number of these 
adipocytokines have been linked to alterations in insulin sensitivity, 
including adiponectin, leptin, resistin, and tumor necrosis factor-α (TNFα). 
In addition, many of the same signaling molecules have been shown to be 
associated with suppressed hepatic insulin sensitivity, and it is thought that 
adipocytokines may contribute to the development of 
liver fibrosis. 
 
 Fundamental deficits in NAFLD seem to insulin resistance that lead 
to impairement in insulin – mediated release of free fatty acids from 
adipose tissue  Increased uptake of fatty acids by hepatocytes leads to 
mitochondrial beta oxidation overload with consequent accumulation of 
fatty acids within hepatocytes. 
 
In free fatty acids delivery and reesterificetion to triglycerides 
overwhelms ability to form and export VLDL , TGL accumulates in liver . 
In fact, a recent study found that about 26% of hepatic TG accumulation in 
NAFLD patients could be accounted for by de novo lipogenesis 11 FFA 
induces gluconeogenesis pathway and inhibits glucose utilization, this 
leads to increase glucose level , leading to hyperinsulinemia. 
 
Hyperinsulinemia increases synthesis of fatty acids in hepatocytes 
by increasing glycolysis and increases accumulation of triglycerides by 
decreasing hepatic production of apolipoprotein B 100 , thus insulin 
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resistance leads to accumulation of ft in hepatocytes by two mechanisms 1) 
peripheral lipolysis 2) hyperinsulinemia. 
 
Mechanism of second hit steatohepatitis –  
 
The final common pathway for development of steatohepatitis is 
oxidative stress within hepatocytes  Oxidative stress results from 
generation of  ROS  and deficient of antioxidant defences .In a vitro study , 
incubating hepatocytes with free fatty acids increases their ROS production  
12 .Any cause of increased hepatic TNF alpha in NASH will lead to 
increased mitochondrial ROS production. Peroxidation of plasma and 
intracellular membranes may cause  direct cell necrosis, or apoptosis and 
megamitochondria ,while ROS induced expression of FAS – Ligand on 
hepatocyte may induce fratricidal cell death. The aldehyde end products of 
lipid peroxidation can covalently bind to hepatic proteins and initiating a 
potentially  injurious immune response.13 Reactive  oxygen species 
mediated lipid peroxidation potentially explain all of the typical 
histological features of NASH . a key role for lipid peroxidation in the 
pathogenesis of NASH would also explain the association between 
steatosis  and risk of necroinflammation and fibrosis as in animal models 
and NASH , the degree of lipid peroxidation correlates with the severity of 
steatosis 13 Fatty acids in hepatocytes induce to increase in cytochrome P 
450 2E1 and 4A activity,which leads to lipid peroxidation, cytokine 
induction and Fas ligand induction leading to hepatocyte death by activate 
collagen synthesis by stellate cells and activates tissue transglutaminase.  
Increased hepatic expression of the Cytochrome P 450 2 E 1 has been 
shown in both the methionine – choline deficient diet animal model of 
NASH  14, CYP 4 A enzymes can become major catalysts of hepatic 
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microsomal lipid peroxidation.sanyal et al have suggested that increased 
mitochondrial beta oxidation of FFA may be important source of ROS  in 
NASH 15.ROS  deplete hepatic antioxidants and allow accumulation of 
more ROS . Depletion of antioxidants like paraoxanase may enhance 
hepatic damage in steatosis .kupffer cell dysfunction induced by insulin 
resistance leads to increased  phagocytic  activity , decreased anti 
inflammatory IL 10 and increased proinflammatory interferon gamma ,IL  
6 activity, thus increasing necroinflammatory activity.  
 
Progression of fibrosis – stellate cell activation is via non cytokine 
pathway or cytokine pathways. TNF  alpha  stimulates secretion of 
profibrogenic cytokines like IL 6 , TGF beta , PDGF. Studies in alcoholic 
fatty liver  and NASH have shown that the severity of fat correlates with 
the degree of hepatic stellate cell activation.16, 17 .these are principal cells 
in the liver responsible for production of extra cellular matrix proteins and 
leading to fibrosis cytokines are capable of producing all of the classical 
histological features of NASH including hepatocyte cell death or apoptosis 
(TNF alpha ) , neutrophil chemotaxis (IL 8 ) HSC activation and mallory 
bodies formation (TGF beta)18  
 
Role of  genetic factors in NASH is suggested by two recent reports 
of family clustering 19 
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REVIEW OF LITERATURE    
Conditions Associated With Steatohepatitis 
1. Alcoholism 
2. Insulin resistance 
a. Syndrome X 
i. Obesity 
ii. Diabetes 
iii. Hypertriglyceridemia 
iv. Hypertension 
b. Lipoatrophy 
c. Mauriac syndrome 
3. Disorders of lipid metabolism 
a. Abetalipoproteinemia 
b. Hypobetalipoproteinemia 
c. Andersen’s disease 
d. Weber-Christian syndrome 
4. Total parenteral nutrition 
5. Severe weight loss 
a. Jejunoileal bypass 
b. Gastric bypass 
c. Severe starvation 
6. Iatrogenic 
a. Amiodarone 
b. Diltiazem 
c. Tamoxifen 
d. Steroids 
e. Highly active antiretroviral therapy 
7. Refeeding syndrome 
8. Toxic exposure 
a. Environmental 
b. Workplace 
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Grading and Staging of NAFLD 
 
The histologic grade  indicates the activity of the steatohepatitic 
lesion, whereas the stage reflects the degree of fibrosis. 
Grading NAFLD 
1. Macrovesicular steatosis 
Grade 0:None 
Grade 1:Up to 33% 
Grade 2:33%–66% 
Grade 3: _ 66% 
2. Necroinflammatory activity 
Grade 1 (mild) Steatosis up to 66%, occasional ballooned hepatocyte 
(mainly zone 3), scattered intra-acinar 
neutrophils (PMN) _ lymphocytes, no or mild portal inflammation 
Grade 2 (moderate) Steatosis of any degree, obvious zone III ballooning 
degeneration, intra-acinar PMNs, zone III 
perisinusoidal fibrosis may be present, mild to moderate, portal and intra-
acinar inflammation 
Grade 3 (severe) Panacinar steatosis, widespread ballooning, intra-acinar 
inflammation, PMNs associated with 
ballooned hepatocytes, mild to moderate portal inflammation 
Staging NAFLD 
1. Stage 1 Zone III perisinusoidal/pericellular fibrosis; focally or extensively 
present 
2. Stage 2 Zone III perisinusoidal/pericellular fibrosis with focal or 
extensive periportal fibrosis 
3. Stage 3 Zone III perisinusoidal/pericellular fibrosis and portal fibrosis 
with focal or extensive bridging fibrosis 
4. Stage 4 Cirrhosis 
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In a retrospective analysis, those with florid steatohepatitis 
characterized by fat, ballooning degeneration, Mallory bodies, or 
perisinusoidal  fibrosis had a poorer long-term outcome than those with fat  
and only nonspecific lobular inflammation.  In another study, Brunt et al. 
scored a total of 10 findings to develop a grading and staging system for 
NASH shown above. 20, 21  
 
These  included  hepatic macrovesicular steatosis, hepatocellular 
ballooning, intra-acinar inflammation, portal tract inflammation, Mallory’s 
hyaline, acidophil bodies, glycogen nuclei, lipogranulomas, and 
hepatocellular iron. It was found that the serum  alanine aminotransferase 
(ALT) levels correlated with  the severity of the grade of steatohepatitis. 
22,23,24 
 
RISK FACTORS  
 
The risk factors for developing NASH are similar risks for benign 
steatosis. 
 
OBESITY  
 
After exclusion of other risks like alcohol, diabetes ,protein 
malnutrition and drug toxicity, obesity alone is a major risk for the 
development of this syndrome 25.the prevalence of obesity in patients with 
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NAFLD is reported to vary from 30- 100% .in obese patients( BMI  > 30) 
the risk of NAFLD is elevated 4.6 fold .clearly the most significant risk 
factor for development of NASH . lobular hepatitis was found in 8.7% in 
patients in a large series of morbidly obese individuals about to undergo 
surgical small bowel bypass as a treatment for obesity. At autopsy , NASH 
was found in 18.5 % of obese patients.the prevalence of NASH is 3 % in 
lean population, but rises to 19% in obesity and nearly 50 % in morbidly 
obese individuals .NAFLD is more common in individuals with an 
abdominal concentration of fat with lower BMI .26,27,28 Visceral obesity, 
as operationally defined by a large waist circumference, is also considered 
a risk factor for NAFLD 29,30  Visceral adipose tissue is more biologically 
active than subcutaneous adipose tissue and is known to release greater 
quantities of adipocytokines. Visceral adipose tissue is a better predictor of 
altered liver function and insulin resistance than obesity defined by body 
mass index     Of obese individuals found to have NASH at autopsy, of 
which most cases were not suspected ante mortem, 13.8% had bridging 
fibrosis or cirrhosis. The corresponding figure for lean individuals was 
6.6%.32.  NASH is almost always a chronic condition and is most 
frequently associated with obesity (central, as measured by waist 
circumference, and overall, as measured by body mass index [BMI]) and 
type 2 diabetes mellitus.33.  
 
A correlation among BMI , degree of steatosis and severity of liver 
injury has been demonstrated in several studies . The risk and severity of 
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NAFLD increases with the number of components of metabolic syndrome . 
34, Studies have shown a significant correlation between the risk of the 
metabolic syndrome , degree of hepatic steatosis, and hip waist ratio , thus 
highlighting the importance of intra abdominal or visceral fat as predictor 
of NAFLD .35,36 
 
DIABETES  
 
It is frequently associated with hepatic steatosis .it is found in about , 
1/3 of non obese persons with type 2 diabetes at autopsy.NAFLD is 
strongly associated with type 2 DM and glucose intolerance, wih or 
without superimposed obesity. 
 
Patient found to have hepatic steatosis by usg examination are more 
likely to have glucose intolerance and elevated baseline insulin levels. 
circulating insulin levels found in type 2 diabetes patients may be a least 
partly responsible for the accumulation of fat in the liver. Hyperglycemia , 
insulin resistance , hyperinsulinemia , glucose intolerance and type 2 have 
been described in 25 – 75 % of adults patients with NASHand may 
increase the  risk of NASH  more than two foldcompared with that of non 
– diabetics.the prevalence of NAFLD in diabetic patients may also increase 
the risk of cardiovascular disease significantly.  . IR is defined as a 
condition in which higher-than-normal insulin concentrations are needed to 
achieve normal metabolic responses or, alternatively, normal insulin 
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concentrations are unable to achieve normal metabolic responses  
Hyperinsulinemia appears as a consequence of the inability of insulin to 
induce its effect on glucose metabolism, and hence, an abnormally large 
amount of insulin is secreted to achieve a biological response with 
consequent several abnormalities in target organs such as the liver, 
endothelium, and kidneys, and this represents the main feature in the 
metabolic syndrome.37,38 
 
The metabolic and cellular mechanism(s) linking insulin resistance 
to NAFLD are not fully understood. Two studies have found decreased 
insulin extraction by the liver, which contributes to hyperinsulinemia in 
patients with NAFLD 39,40  NAFLD is strongly associated with type 2 DM  
and glucose intolerance with or without superimposed obesity. Increased 
serum insulin and glucose levels also promote de novo lipogenesis by 
upregulating lipogenic transcription factors. NAFLD may in turn result in 
hepatic IR, which is thought to be triggered by hepatic FFA accumulation 
and their metabolites that may exacerbate overall IR. Type 2 DM , 
hyperglycemia, glucose intolerance has been described in 20% - 75% adult 
patients with NASH and increases the risk of NASH more than 2 fold 
compared with that of non – diabetic persons .The association between 
type 2 DM and NAFLD appears strongest in morbidly obese patients. 
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HYPERLIPIDEMIA  
 
Hyperlipidemia has been found in a substantial proportion of 
patients with NAFLD .Data from dallas heart study revealed NAFLD in 
60% of patients with mixed hyperlipidemia. Study from korea of potential 
living donors showed that hyperlipidemia was associated with a greater 
than 2 fold risk of significant (>30%) steatosis .Hyperlipidemia has been 
thought to be a risk factor or clinical marker for development of hepatic 
steatosis and NASH 41 
 
GENDER  
 
In early surveys , female gender was overemphazised and has been 
refuted . The prevalence of NASH is equal in among men and women at 
autopsy and prevalence of hepatic steatosis found by CT imaging 42. 
 
DRUGS  
 
NAFLD has been associated with many drugs and toxins and 
metabolic , surgical and genetic condition, that have abnormal fat 
metabolism and mitochondrial injury . Drugs like 
corticosteroids,estrogens,tamoxifen,amiodarone, diltiazem. Cytotoxic 
drugs like methotrexate, bleomycin, azaserine,tetracycline. There is 
increasing appreciation of lipoatrophy and severe hyperlipidemia 
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associated with development of fatty liver in patients being treated with 
highly active antiretroviral drugs (e.g.,indinavir). This has been associated 
with the development of severe insulin resistance 43,44,45.  Occupational 
exposure to several types of chemicals (e.g., organic solvents and 
dimethylformamide) are also associated with fatty liver disease. 
 
IN ASSOCIATION WITH METABOLIC SYNDROME  
 
NAFLD is now recognized as the hepatic component of the 
metabolic syndrome , which includes hyperlipidemia , glucose intolerance 
, obesity and systemic hypertension.the metabolic syndrome is generally 
defined as 3 or more of the following  given table below.although an 
association between different metabolic abnormalities had been noted for 
several years,  The metabolic syndrome was first publicly described in 
1988 by Reaven. 50. Then called Syndrome , the metabolic syndrome 
consisted of a cluster of metabolic abnormalities, including obesity 
(especially abdominal obesity), insulin resistance, impaired glucose 
metabolism, dyslipidemia, and elevated blood pressure. The metabolic 
syndrome is estimated to affect about 25% of the adult population.  The 
best available definition  
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Risk Factor Defining Level 
Abdominal obesity, given as waist 
circumference   
Men  
Women  
HDL cholesterol 
 
Triglycerides 
Blood pressure  
Fasting glucose  
 
 
>102 cm (40 in) 
>88 cm (35 in) 
Men< 40 mg/dL 
Women< 50 mg/dL 
>150 mg/dL 
>130/>85 mm Hg 
>110 mg/dL 
 
WHO Clinical Criteria for Metabolic Syndrome 
Insulin resistance, identified by 1 of the following: 
● Type 2 diabetes 
● Impaired fasting glucose 
● Impaired glucose tolerance 
● or for those with normal fasting glucose levels (_110 mg/dL), glucose 
uptake below the lowest quartile for background population under 
investigation under hyperinsulinemic, euglycemic conditions 
Plus any 2 of the following: 
● Antihypertensive medication and/or high blood pressure (_140 mm Hg 
systolic or _90 mm Hg diastolic) 
● Plasma triglycerides _150 mg/dL (_1.7 mmol/L) 
● HDL cholesterol _35 mg/dL (_0.9 mmol/L) in men or _39 mg/dL 
(1.0 mmol/L) in women 
● BMI _30 kg/m2 and/or waist:hip ratio _0.9 in men, _0.85 in women 
● Urinary albumin excretion rate _20 _g/min or albumin:creatinine ratio 
_30 mg/g 
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Patient  with metabolic syndrome have a 4 -11 fold higher risk of 
developing NAFLD . Recent findings suggest that components of the 
metabolic syndrome are integrally involved in the pathogenesis of this two 
hit model.  The metabolic syndrome is linked to inflammation and 
oxidative stress 49 , and it has been demonstrated that individuals with the 
metabolic syndrome have increased  lipid peroxidation  46. 47 The 
prevalence of metabolic syndrome in patients with NAFLD ranges from 18 
% - 67 % depending on body weight. 
 
The risk of NASH is elevated threefold . It is largely believed that 
insulin resistance is the central feature in the development of the metabolic 
syndrome. NAFLD is highly prevalent in the general population, is not 
associated with SLD, but is associated with many features of the metabolic 
syndrome. (HEPATOLOGY 2005;42:44-52.)48 . The relationship between 
NAFLD and the metabolic syndrome is becoming increasingly recognized. 
 
Approximately 90% of patients with NAFLD have ≥ 1characteristic 
feature of metabolic syndrome and about 33% have the complete 
diagnosis, placing NAFLD as the hepatic representation of the metabolic 
syndrome51  In the absence of obesity and diabetes, hyperinsulinemia and 
insulin resistance are associated with NAFLD 52  In clinical series, 
individuals with the metabolic syndrome are at greater risk for NAFLD, 
but no data are available at the population level, and the relative 
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contribution of each component of the metabolic syndrome to the risk of 
NAFLD is unknown. 
 
Hamaguchi and colleagues’ study clearly demonstrates the very 
strong relationship between NAFLD and the metabolic syndrome. 
Approximately one third of the patients in this study with NAFLD met the 
criteria for the metabolic syndrome, which is very similar to its reported 
prevalence in Italian patients with NAFLD . 
 
A previous study from Japan demonstrated  new onset of fatty liver 
in 14.3% of 35 519 participants  who had repeated liver ultrasonography 
over a 12-year period (14). The development of fatty liver was associated  
with an increase in BMI of 1 kg/m2 (around 2 to 3 kg),  suggesting that 
relatively small changes in body weight may  exert significant metabolic 
effects 53. 
In Marchesini and colleagues’ Italian study of 304 patients with 
NAFLD but not overt 
diabetes (16), the presence of the metabolic syndrome conferred a higher 
risk for NASH (odds ratio, 3.2 [95% CI, 1.2 to 8.9]) and a high risk for 
advanced fibrosis (odds ratio, 3.5 [CI, 1.1 to 11.2]).54 
 
Another important finding from the current study was that steatosis 
regressed in 16% of patients, although this was less likely in the presence 
of the metabolic syndrome. Regression was associated with was associated 
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with a small weight loss. Insulin resistance and systemic hypertension, 
features of the metabolic syndrome, are independently associated with 
advanced forms of NAFLD. Moderate alcohol consumption seems to 
reduce the risk of NAFLD in the severely obese, possibly by reducing 
insulin resistance.55. It clearly shows that the metabolic syndrome and 
weight gain are risk factors for the disease and for newonset  cases. 
Hamaguchi and colleagues’ findings support the possibility that NAFLD 
might be reversible if BMI and aspects of the metabolic syndrome are 
managed effectively, even without normalization of weight. 
 
In addition to the components of the metabolic syndrome previously 
noted, NAFLD has been associated with several rare disorders of lipid 
metabolism (e.g., abetalipoproteinemia82) and some rare syndromes 
characterized by severe insulin resistance (e.g., lipoatrophic diabetes and 
Mauriac syndrome) The liver disease in abetalipoproteinemia as well as 
lipodystrophy can progress to advanced fibrosis and cirrhosis. NAFLD has 
also been associated with Weber-Christian syndrome. The biochemical 
basis for NAFLD in such syndromes and their natural history are 
unknown and may be variable. 
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CAUSES OF NON ALCOHOLIC FATTY LIVER DISEASE. 
 
Causes of macrovesicular steatosis  
Insulin resistance and hyperinsulinemia  
Obesity  
Type 2 DM  
Drugs  
Corticosteroids 
Estrogens 
 Tamoxifen 
 Amiodarone 
 chloroquine  
nifidipine  and diltiazem   
Metabolic – Wilson disease  
Nutritional  
Starvation  
Protein deficit (kwashiorkor,eating disorders) 
Choline deficiency 
Excess carbohydrate 
Infections – chronic hepatitis C (especially 
genotype 3 ) 
Miscellaneous  
Indian childhood cirrhosis 
Jejunoileal bypass. 
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Causes  of  microvesicular  
steatosis 
 
Drugs  
Valproic acid  
Depletion of mitochondril Co A, beta 
oxidation and blockade of beta 
oxidation enzymes by P450  
Tetracycline  Inhibited beta oxidation , impaired 
hepatic triglyceride secretion. 
Aspirin  Uncoupling oxidative phosphorylation, 
depletion of extramtrochondrial acety 
Co A , which prevents transport of 
fatty acids into the mitochondria. 
 
Nucleoside analogs  Inhibition of mitochondrial DNA 
replication. 
Toxins  
Ethanol  
Diminished mitochondrial NAD 
impairs beta oxidation stress damages  
DNA  
 
Toxic shock syndrome  Unknown bacterial toxins 
Genetic defects  
Acute fatty liver of 
pregnancy  
 
Defects in the beta oxidation ; LCHAD  
defect in a subset of patients 
Beta oxidation defects  
CPT I 
CPT 11 
Ornitine transcarbamylase 
deficiency  
Inadequate substrate for beta oxidation 
Inadequate substrate for beta oxidation 
Inhibition of long and medium chain 
fatty acid beta oxidation by 
ammonium. 
Others  
Reye syndrome  
Cholestasis  
Combined acquired and genetic defects 
in beta oxidation or ureagenesis 
Impaired mitochondrial function by 
bile acids. 
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Microvesicular steatosis is distinguished from macrovesicular 
steatosis on well defined morphologic grounds and also by 
pathophysiologic mechanisms.whereas macrovesicular steatosis is caused 
by an imbalance in the hepatic synthesis and export of TAG , all causes of 
microvesicular steatosis is retained in smaller vesicles distributed 
pancellularly rather than coalescing into large droplets characteristic of 
macrosteatosis is unknown. 
 
CLINICAL FEATURES 
 
Most patients with NAFLD present because abnormal serum 
transamminase levels are discovered incidentally for screening purposes. 
In general patients with NAFLD are aymptomatic .if present , symptoms 
tend to be non – specific and constitutional but may include right upper 
quadrant  discomfort. The most common finding of liver disease is 
hepatomegaly, which has been reported in up to 50% of subjects in 
different studies. Of the various stigmata known, the presence of spider 
nevi and palmar erythema are most common.48 Jaundice, edema, asterixis, 
and signs of portal hypertension occur in those with advanced cirrhosis. 
Muscle wasting may occur as the liver disease in more advanced stages. 
Clinical and laboratory features of non alcoholic fatty liver disease 
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Symptoms  Signs  Laboratory features 
Common  
None (48 % - 
100% of pts ) 
Hepatomegaly  Two to three fold elevation of 
serum ALT and AST levels or 
AST/ALT ratio less than 1 ,serum 
alkaline phosphatase level is 
slightly elevated in one third of 
patients.,normal bilirubin and 
prothrombin levels  
Uncommon  
Vague right upper 
quadrant pain  
Fatigue  
Malaise  
Splenomegaly  
Spider 
angiomata  
Palmar 
erythema  
ascites 
Low titre ANA  
Elevated transferring saturation 
HFE gene mutation. 
  
Hepatomegaly has been described in upto 75 % of patients with 
NAFLD . As with many other types of chronic liver disease, most patients 
with NAFLD in cross-sectional studies are asymptomatic. 
 
In many asymptomatic subjects, elevated ALTlevels are discovered 
when a hepatic panel is ordered to monitor subjects treated with 
antihyperlipidemic drugs. NAFLD is the most common cause for 
unexplained persistent elevation of ALT levels once hepatitis C and other 
known causes of chronic liver disease have been excluded 56. 
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Fatigue is probably the most commonly reported symptom and does 
not correlate well with the severity of the histologic lesion. The 
development of ascites, anasarca, variceal hemorrhage, or symptoms of 
hepatic encephalopathy indicates decompensated cirrhosis jaundice occurs 
late in the course of NASH and  indicates advanced liver disease. 
 
LABORATORY FEATURES  
 
In hospital-based populations of patients with NASH, most subjects 
(50%–90%) have abnormal  aminotransferase activities. The degree of 
enzyme elevation is not marked and is usually between 1 and 4 times the 
upper limit of normal values the serum ALT level usually is greater than 
the AST levels ,in contrast with the pattern of alcoholic hepatitis. The 
AST/ALT ratio is almost never  >2. ALT values do not correlate with the 
degree of steatosis or fibrosis. .The alkaline phosphatase and gamma 
glutamyl transpeptidase levels may be elevated , but the serum bilirubin 
levels , prothrombin time and serum albumin level typically are normal , 
except in patients with NAFLD – associated cirrhosis. Circulating 
concentrations of the liver transaminases, ALT, AST, and to less extent γ-
glutamyltransferase (GGT) are commonly used as markers of NAFLD for 
many years. 
 
Elevated levels are considered a consequence of liver damage due to 
fatty acid infiltration and inflammatory stimuli, and recent findings 
indicate that serum levels of these enzymes are associated with multiple 
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components of the metabolic syndrome. Increases in ALT are positively 
associated with each component of the metabolic syndrome, increased TG, 
glucose, waist circumference, diastolic blood pressure, and reduced HDL-
C levels[19]. In addition, insulin resistance, the prevalence of severe liver 
steatosis, and ALT values have been found to be significantly higher in 
subjects with the metabolic syndrome compared to those with less than 
three of the five clinical features considered for its diagnosis[39]. Recent 
data published from NHANES  found significant association with 
increased ALT and insulin resistance, type  diabetes, and the metabolic 
syndrome[40]. GGT, a less specific marker of liver function, is linked to 
obesity, hypertension, sedentary lifestyle, hyperinsulinemia, dyslipidemia, 
inflammation, and oxidative stress 57Furthermore, GGT concentrations 
have been found to be associated with hypertension in individuals with 
central adiposity57 suggesting the potential for a pathogenic link among 
fatty liver disease, endothelial dysfunction, and cardiovascular risk.58  
Serum and hepatic iron levels may be elevated in patients with NAFLD ,in 
particular serum ferritin may be elevated in 20 – 50 5 of patients with 
NAFLD  In a diabetic subject with NASH, isolated hypoalbuminemia may 
also occur due to proteinuria related to diabetic nephropathy. Hematologic 
parameters are usually normal unless cirrhosis and portal hypertension lead 
to hypersplenism. Across several series,15,102,103 about 10%–25% of 
patients have been noted to have a positive antinuclear antibody, a marker 
of autoimmunity. The significance of this observation is unclear. About 
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30%–50% of patients with NASH have either diabetes or glucose 
intolerance. 
 
A fasting lipid profile shows hypertriglyceridemia in 20%–80% of 
patients.59 ,60 Estimating  insulin resistance  is best measured by rigorous 
technique such as the euglycemic insulin clamp method , since this test is 
difficult in routine clinical environment , simpler tests have been sought . 
several generally accepted methods of approximating the insulin sensitivity 
has been developed based on the product of the fasting insulin multiplied 
by the fasting glucose . two of the most commonly used, the homeostasis 
model (HOMA – IR )  and quantitative insulin sensitivity check index  
(QUICKI ), rely on this product and are mathematically  related. Mean 
HOMA index increases with the stage of fibrosis and could help to 
differentiate stages of fibrosis . An even simpler method is that a product 
of fasting insulin multiplied by fasting insulin > 700 may indicate insulin 
resistance .due to lack of  standardization of insulin assays makes these 
difficult to compare. 61. 
 
DIAGNOSIS  
 
The diagnosis of NAFLD  requires the exclusion of alcohol abuse; a 
daily intake as low as 20 g in female subjects and 30 g in male subjects 
may be sufficient to cause alcohol-induced liver disease in some patients 
(350 mL [12 oz] of beer, 120 mL [4 oz] of wine, and 45 mL [1.5 oz] of 
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hard liquor, each contain 10 g of alcohol). The workup of NAFLD and 
NASH also includes checking into drug abuse, HBV and HCV infections, 
haemochromatosis, autoimmune liver disease and, in younger patients, 
Wilson’s Disease. In special groups of NASH may be accompanied by 
drug- and alcohol-induced liver disease and by HCV and HBV infections. 
The combination of NAFLD/NASH and HCV infection plays a 
particularly important clinical role because in this situation the rate of liver 
fibrosis is increased and the success of antiviral therapy is diminished . 
NASH can be induced by various drugs and toxins including 
corticosteroids, NASH can be induced by various drugs and toxins 
including corticosteroids,amiodarone, methotrexate, tetracycline, 
tamoxifen, and valproate  Thus, one needs to carefully assess the full 
clinical history of patients. In practice NAFLD is often diagnosed by 
combining elevated levels of ALT and gamma-GT with the sonographic 
appearance of an increase in the echodensity of the liver. 
 
Ultrasound of the liver has a high sensitivity and specificity (both 
approaching 90%) for detection of fatty infiltration but does not allow 
assessment of the presence or degree of inflammation and fibrosis. 
Therefore, diagnosis of fat in the liver is easily made by ultrasound but 
diagnosis of NAFLD or NASH can not be made without a liver histology. 
Conventional radiology studies used in the diagnosis of fatty liver include 
ultrasound (US), computed tomography (CT), and magnetic resonance 
(MR) imaging . US can identify hepatic steatosis with reasonable accuracy.  
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Typical criteria used to assess for steatosis include hepatorenal echo 
contrast, liver brightness, deep posterior beam  attenuation, and vascular 
blurring Hamaguchi et al used a 6-point scoring system based on liver 
brightness, attenuation, and vascular blurring on US to evaluate for 
NAFLD and showed 100% specificity and 91.7% sensitivity when 
compared with liver biopsy 62 
 
C T has shown a similar diagnostic yield similar to US. Unenhanced 
CT is accurate in predicting steatosis of greater than 30%, but has been 
shown to be much less accurate in predicting lower-grade steatosis 63. 
Diagnostic accuracy has been improved with unenhanced CT scan using 
liver:spleen attenuation ratios with up to 100% specificity and 82% 
sensitivity for hepatic steatosis greater than 30%.Hepatic steatosis may be 
quantified from MR imaging based on the signal differences between fat 
and water and shows good correlation with microscopic fat content 
 
A novel finding of increased dorsocervical lipohypertrophy in 
patients with NAFLD was described recently by Cheung et al. 
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Interestingly, dorsocervical lipohypertrophy was found to be the single 
greatest contributor to the severity of histologic findings of steatohepatitis 
and may prove to be a useful tool in the diagnosis of NASH.64. 
 
Although efforts to use noninvasive imaging studies to accurately 
grade NAFLD in terms of NASH have been unsuccessful, the 
investigations that use imaging to stage fibrosis in patients, and thus 
identify those with advanced disease, have shown more promise. Transient 
elastography is an ultrasound-based technology that is used to measure 
liver stiffness. In a recent study of 68 patients with NAFLD, a stepwise 
increase in elasticity was shown with severity of hepatic fibrosis.35 This 
study showed good correlation between liver biopsy fibrosis stages 1–4 
and liver stiffness using ROCs with positive predictive values (PPVs) 
between 64% and 93.5% for the varying stages of fibrosis. 
 
Liver biopsy remains the best diagnostic tool for confirming NASH, 
as well as the most sensitive and specific means of providing important 
prognostic information. It is also useful to determine the effect of medical 
treatment, given the poor correlation between histological damage and the 
results of liver tests or imaging studies . Today most pathologists use the 
Brunt description to score the histological degree of NASH  The 
histological features of NAFLD are indistinguishable from those of 
alcohol-induced liver disease. There are two lesions associated with 
NAFLD: (i) predominantly macrovesicular steatosis alone or (ii) 
predominantly macrovesicular steatosis and varying amounts of cytologic 
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ballooning and spotty necrosis, scattered mixed neutrophilic–lymphocytic 
inflammation, glycogen nuclei, Mallory’s hyaline, and perisinusoidal 
fibrosis (NASH). All of the features of steatohepatitis are not present in 
every instance of steatohepatitis. The severity of steatosis can be graded on 
the basis of the extent of involved parenchyma. Brunt’s classification is a 
system that unifies the steatotic and necroinflammatory lesions into a 
“grade” and the types of fibrosis into a “stage”. 
Grade Steatosis Ballooning of 
hepatocytes 
Degree of 
inflammation 
1 <33 % Minimal  Mild  
2 34 – 66% Present  Moderate  
3 >66% Marked  Portal – moderate 
 
Stage  Fibrosis  
1 Perisinusoidal  
2 Perisinusoidal,portal,periportal 
3 Bridging septa 
4 Extensive bridging fibrosis, cirrhosis. 
 
Some factors can help to identify patients with NAFLD in whom the 
liver biopsy may provide the most prognostic information. An age of 45 
years or more, the presence of obesity or type 2 DM, and a ratio of 
AST/ALT  are noteworthy indicators of advanced liver fibrosis. In the 
subgroup of overweight patients with BMI >25, older age, higher BMI, 
and higher levels of ALT and triglycerides are also indicators of more 
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advanced liver fibrosis. In severely obese patients with BMI >35, an IR 
index >5, systemic hypertension, and an elevated ALT level correlate 
strongly with the presence of steatohepatitis, whereas hypertension and 
raised levels of ALT/AST and C-peptide suggest the presence of advanced 
fibrosis81. Both the decision to perform a liver biopsy in clinical practice 
and the timing of the biopsy must be individualized and should include the 
patient in the decision-making process. 
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Scoring Systems for Identifying NAFLD 
 
Scoring systems using one or several clinical and/or laboratory 
parameters to identify patients with NASH from the larger pool of NAFLD 
patients also have been assessed. Palekar et al 62 developed a clinical 
model that sums 5 risks factors for NASH identified on multivariatelogistic 
regression. These factors include age 50 or older, female sex, 
aspartateaminotransferase (AST) level of 45 or greater, BMI of 30 or 
greater, AST/ALT ratio of 0.80 or greater, and hyaluronic acid level of 55 
or greater. Combining 3 or more of these factors yielded a sensitivity of 
73.7% and a specificity of 65.7% for detecting NASH with an ROC of 
0.763. This study provided a relatively simple means of identifying NASH 
patients but requires further validation in a larger study population 65. One 
of the early scoring systems developed called the body mass index; age at 
liver biopsy; alanine aminotransferase; and serum triglycerides (BAAT) 
score used 4 easily determined clinical variables to assess for hepatic 
fibrosis 66. 
 
The development of the FibroTest-FibroSURE (Biopredictive) based 
on _2- macroglobulin, apolipoprotein A1, haptoglobin, total bilirubin, and 
_-glutamyltransferase levels.66 A 90% negative predictive value (NPV) 
for advanced fibrosis and a 70% PPV for advanced fibrosis were noted in 
final analysis. 67. A recent review by Guha et al70 tabulated 29 studies 
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that looked at noninvasive markers of hepatic fibrosis in NAFLD either as 
primary or secondary end points. This comprehensive review identified the 
key variables found in the majority of these studies, which included the 
presence of diabetes, increasing age, increased homeostatic insulin 
resistance, increased AST/ALT ratio, decreased platelets, hyaluronic acid, 
and BMI. Although these models are good in predicting advanced fibrosis 
at any one time point 
TREATMENT  
 
Much like the biomarkers being studied to diagnose NASH 
noninvasively, current therapies are focused on the various pathways 
thought central in the pathogenesis of this disease the only effective 
treatment for NAFLD and NASH is a slow and moderate weight loss. 
Several studies have shown that rapid weight loss (very low calorie diet or 
starving) increases the risk of progression of liver disease and even liver 
failure  Patients should therefore be educated not to induce rapid weight 
loss, but to aim at a weight loss of less than 10% of their body weight over 
6-12 months. it is more important that the patients simply eat healthy foods 
like vegetables and fruits, rich in fibre and complex carbohydrates with a 
low glycemic index; they should avoid meat, saturated fat and products 
with less complex carbohydrates. Data have shown that in the setting of 
obesity, moderate weight loss of approximately 6% via caloric restriction 
improves insulin resistance and intrahepatic lipid content. Furthermore, 
caloric restriction improves serum aminotransferase levels and hepatic 
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histology. A small study by Anderson et al74 showed that extreme weight 
loss via starvation leads to worsening liver histology, including fibrosis. In 
addition, 2 bariatric surgery studies have shown mild worsening of lobular 
inflammation and fibrosis in a subset of patients with a mean weight loss 
of 32 and 38 kg, respectively. Huang et al85 counseled patients to follow a 
1400 kcal/day diet for 12 months in 15 biopsyproven NASH patients with 
a subsequent mean weight loss of 2.9 kg (3% of body weight). Among the 
9 of 15 patients (60%) who had a histopathologic improvement on repeat 
liver biopsy, the average weight loss was 7%.Although it would seem that 
the preponderance of the evidence supports that moderate caloric 
restriction resulting in modest weight loss is helpful in improving 
biochemical parameters, insulin sensitivity, and hepatic steatosis68.69.70. 
  
EXERCISE  
 
Suzuki et al109 found that in a population of 348 male patients who 
received annual health physicals, regular exercise and weight loss over a 1-
year period was associated with a significant improvement in serum 
aminotransferase levels. Hickman et al111 followed up 3 NASH patients 
for 3 months with combined dietary modifications and moderate exercise 
of 150 minutes of aerobic exercise weekly with a mean weight loss of 4% 
of total body weight. Patients who lost weight experienced improvement in 
serum aminotransferase levels that were maintained at 15 months of 
follow-up evaluation provided the weight loss was sustained. Repeat liver 
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biopsy in 14 patients 3–6 months after lifestyle modification showed 
significant improvement in steatosis and fibrosis. 
 
DRUGS 
 
There is no drug proven to be beneficial in NAFLD and NASH; 
therefore no drug has been approved by FDA. drugs that might reverse 
insulin resistance such as metformin and thiazolidinediones (rosiglitazone, 
pioglitazone) are the most promising (Angelico 2007); in smaller studies 
these drugs have shown some histologic improvement of NASH 
(Bugianesi 2004; Belfort 2006). all drugs that induce weight loss might be 
beneficial in NAFLD and NASH, in particular when diet and life-style 
modification do not work. Both sibutramine and orlistat have shown to 
improve some characteristics of NAFLD and NASH such as the 
sonographic degree of liver steatosis as well as the histological degree of 
steatosis and fibrosis (Sabuncu 2003; Derosa 2004, Hussein 2007; 
Harrison 2007). Orlistat. The reversible inhibitor of gastric and pancreatic 
lipase, orlistat, appears to be the most studied weight loss medication used 
in the treatment of NASH. medication is taken with meals and blocks 
approximately 30% of dietary triglycerides. Zelber–Sagi et al115 showed 
steatosis only improved in the orlistat group despite significant weight loss 
in each group. Harrison et al116 obtained repeat liver biopsies at 9 months 
and showed that regardless of regimen, a 9% body weight reduction 
produced improvement in biochemical markers, serum aminotransferase 
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levels, steatosis, and necroinflammation, but no improvement in fibrosis. 
Antioxidants and cytoprotective substances have also been proposed to 
treat NAFLD and NASH including vitamin E, vitamin C, glutathione, 
betaine, acetylcysteine, S-adenosyl-L-methionine and ursodesoxycholic 
acid. After a recent Cochrane analysis, none of these substances has shown 
significant benefit in validated randomized studies (Lirussi 2007). 
Glucagon-like protein-1–receptor agonist (incretin analogs).  
Peptides that are derived from glucagonlike protein-1–receptor 
agonists such as exenatide also may prove to be potential therapeutic 
agents in the treatment of NASH. These incretin analogs have been studied 
extensively in patients with type 2 diabetes mellitus and have been found 
to promote insulin secretion, suppress inappropriate glucagon secretion, 
slow gastric emptying, induce satiety, and are associated with modest 
weight loss .71. 
 
Insulin-Sensitizing Medications 
 
Thiazolidinediones improve insulin resistance in skeletal muscle, 
adipose tissue, and the liver through their action as peroxisome 
proliferator–activated receptor _ agonists that increase plasma adiponectin 
levels and fatty acid oxidation and decrease fatty acid synthesis. These 
agents have been the most studied insulin sensitizers used in the treatment 
of NASH. A preliminary study of 22 NASH patients (50% with impaired 
glucose tolerance or diabetes) treated for 48 weeks with rosiglitazone 
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showed overall improvement in insulin sensitivity and serum 
aminotransferase levels. Repeat liver biopsy at 48 weeks showed 
significant improvement in necroinflammation, ballooning, and zone 3 
perisinusoidal fibrosis with 45% (10 patients) no longer meeting criteria 
for NASH. Another pilot study compared pioglitazone 30 mg/day plus 
vitamin E 400 IU/day with vitamin E alone and showed improvement in 
steatosis in both groups but improvement in hepatic inflammation and 
fibrosis in the pioglitazone plus vitamin E arm only.72. 
 
Metformin  
 
Metformin is a biguanide that improves insulin sensitivity by 
decreasing hepatic gluconeogenesis and limiting triacylglycerol 
production. Animal model data has been promising, with early studies of 
obese mice given metformin showing improved serum transaminase levels, 
hepatomegaly, and steatosis.140 open-label RCT in 110 NAFLD patients 
was performed in Italy that compared metformin treatment with 2 control 
groups of vitamin E 800 IU/day or a prescriptive, weight-reducing diet.144 
Metformin showed higher rates of aminotransferase normalization. Repeat 
liver biopsy in 31% of the metformin group showed improvement in 
steatosis, necroinflammation, and fibrosis74,75. Overall, the insulin-
sensitizing medications show the most promise to date in improving 
histopathology in patients with NASH.73.  
 
43 
 
Antioxidant therapy 
 
The depletion of antioxidants within hepatocytes resulting in 
impaired ROS inactivation is the basis for antioxidant supplementation as a 
potential treatment for NASH. 77 The lipid-soluble antioxidant,  tocopherol 
(vitamin E), has been shown to inhibit lipid peroxidation and suppress 
inflammatory cytokines such as tumor necrosis factor-_, and its use in the 
treatment of NASH has been studied. One study comparing 6 months of 
1000 IU vitamin E and 1000 mg vitamin C daily vs placebo showed 
significant improvement in hepatic fibrosis within the vitamin group but 
not between groups and no change in serum aminotransferase levels or 
hepatic inflammation 76 . 
 
Ezetimibe 
 
Ezetimibe (Zetia, Kenilworth, NJ) is another lipid-lowering 
medication that may have hepatic benefits in the treatment of NASH. This 
medication selectively inhibits intestinal cholesterol absorption and in 
controlled studies with statins appears to lower serum LDL cholesterol by 
24% as well as triglycerides by 16%.161 A recent study by Deushi et al 
showed improved insulin resistance and decreased lipid deposition and 
fibrosis in obese rats treated with ezetimibe. No clinical trials with this 
therapy have been published 
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Liver transplantation for NASH 
 
LTX is the final option for patients with end-stage liver disease due 
to cirrhosis and complications of portal hypertension with NASH. Due to 
the increase in the prevalence of NASH, there is also an increase in LTX 
done for end-stage liver disease caused by NASH. However, NASH can 
recur after LTX, particularly if patients have previously undergone 
jejunoileal bypass surgery (Kim 1996; Requart 1995; Weston 1998; Contos 
2001; Burke 2004)79. LTX does not cure the metabolic defect that causes 
NASH . 
 
Surgery for obesity 
 
Gastric bypass has also recently been shown to improve NASH (Liu 
2007; de Almeida 2006; Furuya 2007) 80 however, surgery is usually 
restricted to patients with massive obesity . 
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AIM OF STUDY  
 
1) To determine the fatty liver index in general population by using the 
potential predictors of  fatty liver like age , gender, SGOT, SGPT, 
GGT, BMI, hip waist ratio , fasting glucose, fasting insulin, 
triglycerides and serum cholesterol.  
2) To help physician to select patients for liver biopsy and to decide on 
the treatment. 
3) To advice intensified lifestyle counseling to high risk individuals. 
 
MATERIALS AND METHODS   
 
This study was conducted at PSG Medical college and hospital, 
Coimbatore.  The study participants were the individuals attending the 
master health check up clinic and diagnosed to have fatty liver by 
ultrasonogram. 
 
A total number of 206 were included in the study. They were 
divided equally into cases and controls based on the presence/absence of 
fatty liver by ultrasound. This study was done during June 2010 to 
November 2011. The lab results of the study participants were obtained 
from the computer database and were used to determine the fatty liver 
index. 
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STUDY DESIGN – Prospective case control study. 
 
SAMPLE SIZE  
 
Based on inclusion and exclusion criteria, 104 patients with fatty 
liver and 104 patients without fatty liver were enrolled.  The identification 
of fatty liver was done by ultrasonographically by  hyperechogenicity  or 
brightness of the liver  
 
INCLUSION CRITERIA  
Age more than 18 years 
Participants diagnosed to have fatty liver in ultrasound abdomen 
Non - Alcoholic  
Non - Diabetic 
 
EXCLUSION CRITERIA  
Alcoholic  
Hypothyroidism  
Decompensated liver disease 
Cirrhosis of liver. 
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EVALUATION AND INVESTIGATION   
BODY MASS INDEX 
HIP WAIST RATIO 
FASTING INSULIN LEVEL 
FASTING LIPID PROFILE 
LIVER FUNCTION TEST 
FASTING GLUCOSE LEVEL 
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RESULTS  
 
Table 1 gives the characteristics of the subjects with and without 
fatty liver 
Group Statistics  
age 
Fatty liver 103 50.2115 9.63980 .94526  
No fatty liver 103 52.3365 11.65742 1.14310 0.107 
sex 
Fatty liver 103 1.3846 .48886 .04794  
No fatty liver 103 1.4712 .50158 .04918 0.208 
insulin 
Fatty liver 103 20.1143 10.95720 1.07444  
No fatty liver 103 21.4413 9.64183 .94546 0.211 
LDL 
Fatty liver 103 1.3119E2 37.99951 3.72616  
No fatty liver 103 1.4315E2 47.31402 4.63952 0.319 
HDL 
Fatty liver 103 36.7788 7.74842 .75979  
No fatty liver 103 47.8173 10.70683 1.04989 0.000 
GGT 
Fatty liver 103 1.9084E2 104.06954 10.20486  
No fatty liver 103 1.4861E2 61.80857 6.06083 0.002 
TGL 
Fatty liver 103 1.8729E2 52.85475 5.18283  
No fatty liver 103 1.7017E2 44.55049 4.36854 0.000 
SGOT 
Fatty liver 103 37.0962 21.34257 2.09281  
No fatty liver 103 29.4135 11.03710 1.08228 0.132 
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SGPT 
Fatty liver 103 44.5962 35.02967 3.43494  
No fatty liver 103 30.9327 12.46998 1.22278 0.092 
cholesterol 
Fatty liver 103 1.3526E2 203.36117 19.94120  
No fatty liver 103 98.6635 32.62902 3.19954 0.036 
BMI 
Fatty liver 103 25.7786 2.83749 .27824  
No fatty liver 103 23.7288 2.60499 .25544 0.000 
FBS 
Fatty liver 103 1.1776E2 35.51794 3.48282  
No fatty liver 103 1.4825E2 55.63835 5.45579 0.000 
WAIST 
Fatty liver 103 1.7160 .51284 .05029  
No fatty liver 103 .9212 .28985 .02842 0.000 
 
From the above variables - the predictors identified more 
frequently are HDL (p=0.000), GGT (p=0.002), triglycerides (p=0.000), 
insulin (p=0.211), BMI (p=0.000), FBS (p=0.000),  Hip waist 
ratio(p=0.000) 
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Table 2 shows the inclusion of the above selected variables by binary 
logistic regression analysis with stepwise likelihood ratio method  
Variables in the Equation
  
B S.E. Wald df Sig. Exp(B) 
95.0% C.I.for 
EXP(B) 
  Lower Upper
Step 1a 
WAIST -5.032 .701 51.527 1 .000 .007 .002 .026 
Constant 6.275 .865 52.667 1 .000 531.318   
Step 2b 
HDL .108 .024 19.991 1 .000 1.114 1.062 1.167 
WAIST -4.855 .745 42.428 1 .000 .008 .002 .034 
Constant 1.539 1.254 1.506 1 .220 4.660   
Step 3c 
HDL .100 .026 14.975 1 .000 1.105 1.051 1.162 
TGL -.014 .005 9.362 1 .002 .986 .977 .995 
WAIST -5.926 .986 36.089 1 .000 .003 .000 .018 
Constant 5.172 1.803 8.232 1 .004 176.342   
]\ Step 4d 
HDL .107 .029 13.782 1 .000 1.113 1.052 1.177 
TGL -.024 .007 11.883 1 .001 .976 .963 .990 
FBS .034 .011 9.441 1 .002 1.034 1.012 1.057 
WAIST -6.242 1.127 30.698 1 .000 .002 .000 .018 
Constant 2.240 1.994 1.262 1 .261 9.391 
Step 5e HDL .089 .031 8.060 1 .005 1.093 1.028 1.163
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TGL -.029 .008 13.962 1 .000 .971 .956 .986 
BMI -.276 .106 6.806 1 .009 .759 .616 .934 
FBS .037 .012 9.559 1 .002 1.038 1.014 1.063
WAIST -6.418 1.204 28.393 1 .000 .002 .000 .017 
Constant 10.389 3.831 7.353 1 .007 3.250E4   
Step 6f 
HDL .098 .035 7.817 1 .005 1.102 1.030 1.180
TGL -.028 .008 11.570 1 .001 .972 .956 .988 
GGT -.020 .007 7.273 1 .007 .981 .967 .995 
BMI -.370 .126 8.580 1 .003 .691 .539 .885 
FBS .037 .012 9.318 1 .002 1.038 1.013 1.063
WAIST -6.608 1.247 28.097 1 .000 .001 .000 .016 
Constant 15.974 4.920 10.541 1 .001 8.654E6   
 
a. Variable(s) entered on step 1: WAIST. 
b. Variable(s) entered on step 2: HDL. 
c. Variable(s) entered on step 3: TGL.  
d. Variable(s) entered on step 4: FBS.  
e. Variable(s) entered on step 5: BMI.  
f. Variable(s) entered on step 6: GGT  
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The above model based on the 6 remaining predictors fitted well 
with p value of 0.339 by Homer – Lemeshow statistics,and had a ROC – 
AUC of 0.00 (95%CI )  
 
These variables were multiplied by using the formula below. 
 
FLI = (e - 0.014*loge (triglycerides) - 0.370*BMI + 0.108*loge 
(hdl)  -5.032 waist circumference +0.037* FBS -0.020* ggt   - 15.974)  / 
(1 + e - 0.014*loge (triglycerides) - 0.370*BMI + 0.108*loge (hdl)  -
5.032 waist circumference +0.037* FBS -0.020* ggt   - 15.974) * 100 
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The sensitivity and specificity of the ROC curve are shown below  
Coordinates of the Curve
Test Result Variable(s):newlogistic
Positive or greater 
than equal to 
Sensitivity 1 – Specificity 
-1.0000 1.000 1.000 
.0000 .990 1.000 
.0000 .981 1.000 
.0000 .971 1.000 
.0000 .962 1.000 
.0000 .952 1.000 
.0001 .942 1.000 
.0001 .933 1.000 
.0001 .923 1.000 
.0001 .913 1.000 
.0002 .904 1.000 
.0002 .894 1.000 
.0002 .885 1.000 
.0002 .875 1.000 
.0008 .865 1.000 
.0017 .856 1.000 
.0020 .846 1.000 
.0023 .837 1.000 
.0025 .827 1.000 
.0028 .817 1.000 
.0036 .808 1.000 
.0051 .798 1.000 
.0065 .788 1.000 
.0083 .779 1.000 
.0103 .769 1.000 
.0116 .760 1.000 
.0122 .750 1.000 
.0125 .740 1.000 
.0134 .731 1.000 
.0149 .721 1.000 
.0163 .712 1.000 
.0181 .702 1.000 
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.0196 .692 1.000 
.0219 .683 1.000 
.0307 .673 1.000 
.0380 .663 1.000 
.0412 .654 1.000 
.0485 .644 1.000 
.0631 .635 1.000 
.0785 .625 1.000 
.0926 .615 1.000 
.1028 .606 1.000 
.1056 .596 1.000 
.1082 .587 1.000 
.1336 .577 1.000 
.1626 .567 1.000 
.1989 .558 1.000 
.2418 .548 1.000 
.2776 .538 1.000 
.3445 .529 1.000 
.3901 .519 1.000 
.4109 .510 1.000 
.4687 .500 1.000 
.5317 .490 1.000 
.5847 .481 1.000 
.6759 .471 1.000 
.7529 .462 1.000 
.8021 .452 1.000 
.8825 .442 1.000 
.9338 .433 1.000 
.9615 .423 1.000 
.9958 .413 1.000 
1.0266 .404 1.000 
1.0749 .394 1.000 
1.1070 .385 1.000 
1.2851 .375 1.000 
1.7432 .365 1.000 
2.3506 .356 1.000 
3.0526 .346 1.000 
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3.6206 .337 1.000 
4.1034 .327 1.000 
4.4432 .317 1.000 
4.9968 .308 1.000 
5.7504 .298 1.000 
7.1761 .288 1.000 
8.6202 .279 1.000 
9.2767 .269 1.000 
9.7915 .260 1.000 
10.2206 .250 1.000 
12.1860 .240 1.000 
14.0684 .231 1.000 
14.6197 .231 .990 
15.7139 .221 .990 
16.5579 .212 .990 
17.5653 .202 .990 
18.5365 .192 .990 
18.7593 .192 .981 
19.8752 .183 .981 
21.8772 .173 .981 
23.4631 .163 .981 
24.3188 .154 .981 
25.8106 .144 .981 
27.2545 .135 .981 
29.6765 .125 .981 
31.8883 .125 .971 
32.2043 .125 .962 
33.0383 .115 .962 
33.9315 .115 .952 
37.8232 .096 .952 
43.3800 .096 .942 
46.0001 .096 .933 
46.8013 .087 .933 
47.2926 .087 .923 
49.9636 .077 .923 
52.5479 .077 .913 
54.0992 .077 .904 
57 
 
60.1028 .067 .904 
65.3018 .067 .894 
68.5349 .058 .894 
72.2352 .058 .885 
73.6662 .048 .885 
74.4463 .048 .875 
74.7570 .038 .875 
76.7833 .029 .875 
78.9581 .029 .865 
79.9972 .029 .856 
81.0782 .029 .846 
82.5313 .029 .837 
84.3945 .019 .837 
85.0158 .019 .817 
85.0669 .019 .808 
85.4709 .019 .798 
85.8401 .019 .788 
86.0307 .019 .779 
86.2424 .019 .769 
86.3099 .019 .760 
86.6272 .019 .750 
87.2522 .019 .740 
87.8543 .019 .731 
88.1989 .019 .721 
88.5121 .019 .712 
88.7634 .019 .702 
89.1388 .019 .692 
89.8402 .019 .683 
90.8263 .019 .673 
91.7518 .019 .663 
92.2325 .019 .654 
92.5701 .019 .644 
92.8583 .019 .635 
93.1609 .019 .625 
93.5251 .019 .615 
93.8183 .019 .606 
93.9942 .019 .596 
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94.1229 .019 .587 
94.2782 .019 .577 
94.4994 .019 .567 
94.8683 .019 .558 
95.3898 .019 .548 
95.8015 .019 .538 
96.2360 .019 .529 
96.5974 .019 .519 
96.8645 .019 .510 
97.3418 .019 .500 
97.6262 .019 .490 
97.6303 .019 .481 
97.7937 .019 .471 
97.9815 .019 .462 
98.1589 .019 .452 
98.3428 .019 .442 
98.3828 .019 .433 
98.4189 .019 .423 
98.5347 .019 .413 
98.6355 .019 .404 
98.6561 .010 .404 
98.6812 .010 .394 
98.7047 .010 .385 
98.7643 .010 .375 
98.8388 .010 .365 
98.8700 .000 .365 
98.9018 .000 .356 
98.9458 .000 .346 
98.9984 .000 .337 
99.0733 .000 .327 
99.1589 .000 .317 
99.2105 .000 .308 
99.2596 .000 .298 
99.3362 .000 .288 
99.4079 .000 .279 
99.4902 .000 .269 
99.5450 .000 .260 
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99.5584 .000 .250 
99.6461 .000 .240 
99.7325 .000 .231 
99.7449 .000 .221 
99.7504 .000 .212 
99.7564 .000 .202 
99.7675 .000 .192 
99.7774 .000 .183 
99.7877 .000 .173 
99.8162 .000 .163 
99.8391 .000 .154 
99.8461 .000 .144 
99.8782 .000 .135 
99.9042 .000 .125 
99.9109 .000 .115 
99.9191 .000 .106 
99.9297 .000 .096 
99.9382 .000 .087 
99.9399 .000 .077 
99.9445 .000 .067 
99.9491 .000 .058 
99.9523 .000 .048 
99.9565 .000 .038 
99.9671 .000 .029 
99.9837 .000 .019 
99.9960 .000 .010 
100.9999 .000 .000 
 
 The smallest cutoff value is the minimum observed test value 
minus 1, and the largest cutoff value is the maximum observed test 
value plus 1. All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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Based on the ROC value the following table gives the cut – off value. 
FLI cut point No % 
>10 129 62.31884 
>20 119 57.48792 
>30 113 54.58937 
>40 108 52.17391 
>50 103 49.75845 
>60 101 48.79227 
>70 98 47.343 
>80 91 43.96135 
>90 73 35.2657 
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 As shown above the greatest contribution for FLI was   
triglycerides, GGT , BMI,  hip waist ratio. The above table  gives the 
SN, SP, LR+ and LR- of  FLI. A FLI < 30 can be used to rule out .(SN 
= 54.58 % ) and a FLI ≥ 60 to rule in hepatic steatosis(48.79%)  
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DISCUSSION  
 
The natural history of NAFLD remains poorly understood and the 
search for non – invasive methods with which to identify patients with 
advanced fibrosis and cirrhosis remains a key issue . 
 
In this study, we developed a simple  non invasive system composed 
of routinely measured and easily available variables to find the fatty liver 
index. Our results highlight the utility of a new panel of biochemical 
markers for detection of Fatty Liver Index.  
 
 Among the 103 patients included in this study according to 
inclusion criteria the major predictors were BMI , hip waist ratio, low HDL 
levels, triglyceride, GGT and fasting glucose level.   
Although  age  increase the risk of obesity and metabolic syndrome 
NAFLD is not systematically associated with age. 82.   In this study age 
is not associated in any of the multivariate models. 
 
According to gender ,this study does not support the hypothesis 
that any specific gender is a risk factor for NAFLD in the general 
population  which is similarly quoted in a study done in a general 
population 47. 
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 In a study  both normal liver and alcoholic liver disease were less 
likely seen than  NAFLD in obese subjects, 38 confirming that BMI is an 
independent predictor of NAFLD. In  this study BMI  and hip waist ratio 
were the strongest predictor of fatty liver in the final model. 
 
Among liver enzymes , GGT was an independent predictor of 
fatty liver while SGOT and SGPT was not associated with fatty liver in 
this study..In many previous studies  an elevated SGPT did  discriminate 
NAFLD either from normal liver or from alcoholic fatty liver , indicating 
that this enzyme is not an independent predictor of NAFLD . These 
findings confirmed that there is a high prevalence of NAFLD in subjects 
without elevated SGPT in general population and that the use of elevated  
SGPT  as a marker of NAFLD  has to be discouraged. 
 
Triglycerides were the independent predictor of fatty liver as 
confirmed by previous studies.83. Fasting glucose were also a important 
predictor after exclusion of insulin in this study.In both normal liver and 
alcoholic fatty liver hyperglycemia were less likely than in NAFLD , 
confirming that an altered glucose metabolism is a risk factor for NAFLD . 
Importantly, hyperglycemia was associated with a greater risk of NAFLD 
independently from hyperlipidemia even after exclusion of insulin on the 
contrary  insulin was not identified as an independent predictor in this 
study.  
64 
 
Level of HDL cholesterol were low in this study   as confirmed 
by previous study  done in a general  population Shangai , China sept 
2005 indicated that the prevalence of Obesity, diabetes, hypertension, and 
dyslipidemia were all significantly higher in fatty liver in patients than in 
controls. In contrast , the level of HDL cholesterol were markedly lower 
and our study was done to find if these results are consistent in a Indian 
population. 
 
As these variables are easily applied this fatty liver index is easy to 
employ in routine practices. in our population a FLI <30 ruled out and a 
FLI >60 ruled in  hepatic steatosis as detected by ultrasonography 
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CONCLUSION 
 
 Fatty liver is highly prevalent in our country and is related to 
multiple metabolic risk factors.  
 In conclusion this study shows that BMI, hip waist ratio, low HDL 
levels, triglyceride, GGT and fasting glucose level are good 
predictors of fatty liver.  
 Hepatic steatosis can be ruled out by using the FLI which is a non 
invasive tool in a comunity level. 
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